delivery to deep seeded tissues yes, but not to skin, and the issue with past delivery problems has been the amount of DNA that gets in for the desired effect....CYGX circumvents this by having a vector that creates ssSNA intracellularly...that means when just a little gets in, the vector produces more than enough ssDNA for its desired effect.... so please no more talk of the delivery problem...the only delivery problem is of CYGX getting to the right ears for financing, and financing the company properly.
This stock will move, in time...hopefully sooner than later.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.